Cara TherapeuticsCARA
About: Cara Therapeutics Inc is a development-stage biotechnology company involved in the development of novel therapeutics to treat human diseases associated with inflammation, pain, and pruritus. Cara's most advanced compound, CR845, aims to treat acute pain and pruritus. This patented compound has analgesic, anti-inflammatory, and antipruritic properties that can be used for multiple therapeutic applications. Additionally, Cara's objective is to use its proprietary drug-screening technology to develop a future pipeline of first-in-class molecules with analgesic and anti-inflammatory features.
Employees: 55
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
11.04% less ownership
Funds ownership: 43.39% [Q1] → 32.35% (-11.04%) [Q2]
19% less funds holding
Funds holding: 100 [Q1] → 81 (-19) [Q2]
40% less repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 25
54% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 35
79% less capital invested
Capital invested by funds: $21.8M [Q1] → $4.56M (-$17.2M) [Q2]
Research analyst outlook
We haven’t received any recent analyst ratings for CARA.